Live Breaking News & Updates on வாய்வழி வாதம்|Page 20
Stay updated with breaking news from வாய்வழி வாதம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(2) Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer s disease New pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson s disease will be featured in two separate presentations DUBLIN, Ireland, Feb. 24, 2021 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced three oral presentations and participation in a live forum at The 15 th International Conference on Alzheimer s and Parkinson s Diseases (AD/PD 2021). Prothena will present new preclinical data demonstrating that targeting a novel epitope with PRX005, an anti-tau antibody, resulted in superior attributes for the potential trea ....
20 Feb 2021 - 9:41 The Peninsula Doha: More commonly known as gum disease, periodontitis is a severe gum infection characterised by chronic inflammation, whose patients may be at greater risk if exposed to COVID-19. A research team spearheaded by Dr. Nadia Maarouf, Associate Consultant from Hamad Dental Center, and led by Dr. Faleh Tamimi, Professor at Qatar University’s (QU) College of Dental Medicine, has demonstrated that there may be a strong association between COVID-19 and oral health. While speaking on his research about patients with (periodontitis), Dr. Faleh said: “In our study, we assessed the dental records of patients that have been infected with COVID-19. We discovered that a substantial portion of the patients that suffered severe COVID-19 complications (including death) had chronic gum infections, also known as periodontal disease. Our study concludes that there is a strong association between the severity of COVID-19 and the presence of pe ....
DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients [6], as compared to placebo (FAS). - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS). ....
(2) DUBLIN, Feb. 16, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the completion of the rolling submission for the supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of adult patients with idiopathic hypersomnia. If approved, Xywav will be the first and only approved treatment in the U.S. for adults with idiopathic hypersomnia. Xywav received Fast Track designation by the FDA in September 2020 for the treatment of idiopathic hypersomnia. Jazz was granted rolling submission by FDA for this sNDA in December 2020, permitting the submission of portions of the proposed application as they were completed. ....